Summary:
Phase 3 randomized, controlled open-label study of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Qualified Participants Must:
• Be 18 and older
•
Had at least 1 prior anti-MM regimen and no more than 3
•
Progression evidence
Qualified Participants May Receive:
Selinexor will be provided at no cost